Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.46 |
| ▸ | PRF1 | P14222 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601168 | 0.77 | MAP4K4 (0.53) | LOXL2CSNK2A1HSD17B1HSD17B2MAOA | |
| SCHEMBL29709318 | 0.77 | CDK8 (0.53) | CA1CA2CA9CA4CA12 | |
| SCHEMBL21074248 | 0.77 | CDK8 (0.53) | CA1CA2CA9CA4CA12 | |
| SCHEMBL69900 | 0.76 | CSNK2A1 (0.62) | LOXL2CSNK2A1KDRIKBKB | |
| Bromide SCHEMBL22834317 | 0.75 | CSNK2A1 (0.61) | LOXL2CSNK2A1KDRIKBKB | |
| Hydrochloric Acid SCHEMBL11145599 | 0.75 | CSNK2A1 (0.61) | LOXL2CSNK2A1KDRIKBKB | |
| SCHEMBL9954813 | 0.74 | ALDH1A1 (0.54) | LOXL2CSNK2A1KDRHSD17B1HSD17B2 | |
| SCHEMBL2406426 | 0.74 | CSNK2A1 (0.49) | LOXL2CSNK2A1HSD17B1HSD17B2 | |
| SCHEMBL2406300 | 0.74 | KDM4E (0.54) | LOXL2CSNK2A1KDRHSD17B1HSD17B2 | |
| SCHEMBL29389381 | 0.74 | CSNK2A1 (0.49) | LOXL2CSNK2A1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860598-B1 | VEMURAFENIB AND SALTS THEREOF FOR USE IN THE TREATMENT OF ENTEROVIRAL INFECTIONS | JYVAESKYLAEN YLIOPISTO (FI) | 2023-09-06 | — | — | EP | disclosed |
| US-20210244716-A1 | Vemurafenib and salts thereof for use in the treatment of enteroviral infections | Jyväskylän Yliopisto (FI) | 2021-08-12 | — | — | US | disclosed |
| EP-3860598-A1 | VEMURAFENIB AND SALTS THEREOF FOR USE IN THE TREATMENT OF ENTEROVIRAL INFECTIONS | Jyväskylän Yliopisto (FI) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070390-A1 | VEMURAFENIB AND SALTS THEREOF FOR USE IN THE TREATMENT OF ENTEROVIRAL INFECTIONS | Jyväskylän Yliopisto (FI) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244716-A1 | Vemurafenib and salts thereof for use in the treatment of enteroviral infections | BRAF, VHL, ETV6 | LOXL2 3637/4885CSNK2A1 3554/4885CA1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.